Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

Date publication

octobre 2016

Journal

The American journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27481308

Résumé

Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.

Mots clés

Adrenal Cortex Hormones, therapeutic use, Age of Onset, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, therapeutic use, Azathioprine, therapeutic use, Carcinoma, epidemiology, Colitis, Ulcerative, drug therapy, Colorectal Neoplasms, epidemiology, Crohn Disease, drug therapy, Female, Follow-Up Studies, France, epidemiology, Humans, Immunosuppressive Agents, therapeutic use, Incidence, Inflammatory Bowel Diseases, drug therapy, Intestinal Neoplasms, epidemiology, Lymphoproliferative Disorders, epidemiology, Male, Mesalamine, therapeutic use, Methotrexate, therapeutic use, Middle Aged, Myeloproliferative Disorders, epidemiology, Neoplasms, epidemiology, Proportional Hazards Models, Protective Factors, Registries, Retrospective Studies, Risk Factors, Time Factors, Tumor Necrosis Factor-alpha, antagonists & inhibitors

Référence

Am. J. Gastroenterol.. 2016 Oct;111(10):1428-1436